Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Institut National de la Recherche Agronomique, Jouy-en-Josas
Vaccine based on live lactococci protects against HPV-induced tumors
February 5th, 2006
A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. According to recent research from France and Mexico, "Current strategies to prevent or treat human papillomavirus type 16 (HPV-16) infection are promising, but remain costly. More economical but efficient vaccines are thus needed. In this study, we evaluated the protective effects of mucosally co-administered live Lactococcus lactis strains expressing cell wall-anchored E7 antigen and a secreted form of IL-12 to treat HPV-16-induced tumors in a murine model." ...
Source: Women's Health Law Weekly (2006-02-05)
|
